SK112999A3 - Phytosterol composition for preventing alzheimer's disease - Google Patents

Phytosterol composition for preventing alzheimer's disease Download PDF

Info

Publication number
SK112999A3
SK112999A3 SK1129-99A SK112999A SK112999A3 SK 112999 A3 SK112999 A3 SK 112999A3 SK 112999 A SK112999 A SK 112999A SK 112999 A3 SK112999 A3 SK 112999A3
Authority
SK
Slovakia
Prior art keywords
disease
apo
alzheimer
beta
sitosterol
Prior art date
Application number
SK1129-99A
Other languages
English (en)
Slovak (sk)
Inventor
Egon Novak
Original Assignee
Forbes Medi Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forbes Medi Tech Inc filed Critical Forbes Medi Tech Inc
Publication of SK112999A3 publication Critical patent/SK112999A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK1129-99A 1997-12-18 1998-12-18 Phytosterol composition for preventing alzheimer's disease SK112999A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/993,901 US5985936A (en) 1997-12-18 1997-12-18 Method of preventing and delaying onset of Alzheimer's disease and composition therefor
PCT/CA1998/001147 WO1999032097A2 (en) 1997-12-18 1998-12-18 Phytosterol composition for preventing alzheimer's disease

Publications (1)

Publication Number Publication Date
SK112999A3 true SK112999A3 (en) 2001-11-06

Family

ID=25540052

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1129-99A SK112999A3 (en) 1997-12-18 1998-12-18 Phytosterol composition for preventing alzheimer's disease

Country Status (18)

Country Link
US (1) US5985936A (bg)
EP (1) EP0967982A2 (bg)
CN (1) CN1252724A (bg)
AU (1) AU1656099A (bg)
BG (1) BG103740A (bg)
BR (1) BR9807577A (bg)
CA (1) CA2281710A1 (bg)
EE (1) EE9900354A (bg)
GE (1) GEP20022783B (bg)
HU (1) HUP0100737A3 (bg)
LT (1) LT4801B (bg)
LV (1) LV12438B (bg)
MD (1) MD1920F2 (bg)
NO (1) NO993979L (bg)
PL (1) PL335421A1 (bg)
RU (1) RU2173151C2 (bg)
SK (1) SK112999A3 (bg)
WO (1) WO1999032097A2 (bg)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8679534B2 (en) * 1997-12-12 2014-03-25 Andrx Labs, Llc HMG-CoA reductase inhibitor extended release formulation
EP1225880A2 (en) * 1999-11-04 2002-07-31 Andrx Corporation Use of a hmg-coa reductase inhibitor for treating amyloid beta precursor disorders
US20020107173A1 (en) * 1999-11-04 2002-08-08 Lawrence Friedhoff Method of treating amyloid beta precursor disorders
US6610320B2 (en) 2000-04-14 2003-08-26 Mars, Incorporated Compositions and methods for improving vascular health
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US20030013692A1 (en) * 2001-01-19 2003-01-16 Gullans Steven R. Methods of treating neurological disorders
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
WO2002064735A2 (en) * 2001-02-12 2002-08-22 Akzo Nobel N.V. Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
DE10154221A1 (de) * 2001-11-07 2003-05-15 Max Delbrueck Centrum Mittel zur Behandlung von Läsionen des Nervensystems
FR2848452B1 (fr) * 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
ES2318274T3 (es) 2003-03-07 2009-05-01 Schering Corporation Compuestos de azetidinona sustituida, formulaciones y uso de los mismos para el tratamiento de hipercolesterolemia.
JP5137228B2 (ja) 2003-03-07 2013-02-06 メルク・シャープ・アンド・ドーム・コーポレーション 高コレステロール血症の処置のための置換アゼチジノン化合物、置換アゼチジノン処方物およびそれらの使用
MXPA05009502A (es) * 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
US20080182801A1 (en) * 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
GB0513881D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
JP2007526764A (ja) * 2004-01-22 2007-09-20 ジェネッサンス ファーマシューティカルズ，インコーポレイティド アルツハイマー病の発症年齢に関連するａｐｏｅ遺伝子マーカー
US7704955B2 (en) * 2004-11-24 2010-04-27 Neopro Pain, Inc. Methods and compositions for modulating conditions in both mammals and plants
GB0512726D0 (en) * 2005-06-22 2005-07-27 Btg Int Ltd Multiple sclerosis therapy and diagnosis
GB0513883D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
GB0513888D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
KR20100135847A (ko) * 2008-03-27 2010-12-27 에보텍 뉴로사이언시즈 게엠베하 Ｎｍｄａ ｎｒ２ｂ―서브타입 선택적 길항제를 사용한 질병 치료 방법
WO2010104375A1 (en) * 2009-03-12 2010-09-16 N.V. Nutricia Stigmasterol for the treatment of alzheimer's disease
US10307450B2 (en) 2010-01-11 2019-06-04 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
US10383886B2 (en) 2010-01-11 2019-08-20 Phoenix Biotechnology, Inc. Method of treating neurological conditions with oleandrin
US9011937B2 (en) * 2010-11-22 2015-04-21 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
US9376481B2 (en) 2011-04-26 2016-06-28 The Regents Of The University Of California Methods of promoting CNS neuronal repair by inhibiting LRP-1
CN102813659A (zh) * 2012-08-21 2012-12-12 贵阳中医学院 20α-二甲胺基- 2α-羟基-3β-惕洛酰胺基-5α-孕甾烷的用途
WO2015123617A1 (en) * 2014-02-14 2015-08-20 Arizona Board Of Regents For The University Of Arizona Method for reducing bcl2 gene expression
US10596186B2 (en) 2016-09-14 2020-03-24 Phoenix Biotechnology, Inc. Method and compositions for treating viral infections
US10702567B2 (en) 2016-09-14 2020-07-07 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
US11331291B2 (en) 2017-09-14 2022-05-17 Phoenix Biotechnology, Inc. Method of and improved composition for treating triterpene-responsive conditions, diseases or disorders
KR20200083969A (ko) 2017-09-14 2020-07-09 피닉스 바이오테크놀러지 인코포레이티드. 신경학적 상태를 치료하기 위한 방법 및 개선된 신경보호 조성물
EP3842039A1 (en) * 2019-12-24 2021-06-30 Folium Biosciences Europe B.V. Food supplement comprising cannbinoids and phytosterols for alzheimer
US20230263809A1 (en) 2019-12-24 2023-08-24 Folium Biosciences Europe B.V. Food supplement for alzheimer
US11806359B2 (en) 2020-03-31 2023-11-07 Phoenix Biotechnology, Inc. Method and compositions for treating Coronavirus infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1203515B (it) * 1987-02-26 1989-02-15 Indena Spa Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono
WO1994018994A1 (en) * 1993-02-23 1994-09-01 Pharmakon Usa, Inc. Therapeutic herbal composition
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
ES2464465T3 (es) * 1994-09-29 2014-06-02 Pharmachem Laboratories, Inc. Composiciones de esteroles a partir de jabón de pulpa
CN1179903A (zh) * 1996-10-09 1998-04-29 李辉 营养丝米粉
EP1019044B1 (en) * 1997-05-15 2007-04-11 University of Washington Composition and methods for treating alzheimer's disease and other amyloidoses

Also Published As

Publication number Publication date
NO993979D0 (no) 1999-08-18
LT99114A (lt) 2001-01-25
WO1999032097A2 (en) 1999-07-01
BG103740A (bg) 2000-05-31
RU2173151C2 (ru) 2001-09-10
CN1252724A (zh) 2000-05-10
EE9900354A (et) 2000-02-15
GEP20022783B (en) 2002-09-25
LV12438A (en) 2000-03-20
LV12438B (en) 2000-09-20
HUP0100737A2 (hu) 2001-09-28
MD1920F2 (ro) 2002-05-31
EP0967982A2 (en) 2000-01-05
LT4801B (lt) 2001-06-25
CA2281710A1 (en) 1999-07-01
PL335421A1 (en) 2000-04-25
WO1999032097A3 (en) 1999-09-02
US5985936A (en) 1999-11-16
BR9807577A (pt) 2001-08-07
AU1656099A (en) 1999-07-12
NO993979L (no) 1999-10-13
HUP0100737A3 (en) 2002-07-29
MD990262A (en) 2000-06-30

Similar Documents

Publication Publication Date Title
RU2173151C2 (ru) Способ и композиция для профилактики и задержки начала болезни альцгеймера
Troutwine et al. Apolipoprotein E and Alzheimer's disease
Salem Jr et al. The benefit of docosahexaenoic acid for the adult brain in aging and dementia
Leduc et al. APOE and cholesterol homeostasis in Alzheimer's disease
Anil The impact of EPA and DHA on blood lipids and lipoprotein metabolism: influence of apoE genotype
Hottman et al. HDL and cognition in neurodegenerative disorders
Martin et al. Brain cholesterol in normal and pathological aging
Wang et al. Lipoprotein lipase in the brain and nervous system
Chernick et al. Peripheral versus central nervous system APOE in Alzheimer’s disease: Interplay across the blood-brain barrier
Zhu et al. Lipid metabolism in Alzheimer’s disease
Xiao et al. DHA ameliorates cognitive ability, reduces amyloid deposition, and nerve fiber production in Alzheimer’s disease
Turri et al. Emerging role of HDL in brain cholesterol metabolism and neurodegenerative disorders
JP2004505910A (ja) アポリポタンパク質ｅ分泌を誘導するための方法
Uddin et al. Emerging therapeutic promise of ketogenic diet to attenuate neuropathological alterations in Alzheimer’s disease
Takechi et al. Chylomicron amyloid-beta in the aetiology of Alzheimer's disease
Lovati et al. Increased plasma and aortic triglycerides in rabbits after acute administration of 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin
Wang et al. Dietary n–3 PUFA deficiency increases vulnerability to scopolamine-induced cognitive impairment in male C57BL/6 Mice
Liu et al. Insulin Resistance and impaired branched-chain amino acid metabolism in Alzheimer’s Disease
Paseban et al. The role of the ATP-binding cassette A1 (ABCA1) in neurological disorders: a mechanistic review
Hu et al. Reexamining the Causes and Effects of Cholesterol Deposition in the Brains of Patients with Alzheimer’s Disease
Zhou et al. Prenatal ethanol exposure up-regulates the cholesterol transporters ATP-binding cassette A1 and G1 and reduces cholesterol levels in the developing rat brain
Mas et al. Functional Vitamin E deficiency in ApoE4 patients with Alzheimer’s disease
Pamir et al. Overexpression of apolipoprotein A5 in mice is not protective against body weight gain and aberrant glucose homeostasis
CZ9902921A3 (cs) Léčivo pro profylaxi nebo zpomalení rozvoje Alzheimerovy choroby a terapeuticky účinný produkt k prevenci Alzheimerovy choroby
Plourde Aging, cognitive decline, apolipoprotein E and docosahexaenoic acid metabolism